Combination drug fights lung cancer

Combination of TRAIL receptor targeted agents bortezomib can be used in lung cancer. The combination induces apoptosis in preclinical models of non-small cell lung cancer (NSCLC). This is evident from PhD research by Janet Stege House for NSCLC. Bortezomib is the intrinsic preference for TRAIL receptor 1 or TRAIL receptor 2-induced apoptosis by rhTRAIL in NSCLC cells change and apoptosis via both